Acute treatment with ketamine, an NMDA receptor antagonist, has been reported to be efficacious in treating depression. The goal of our study was to evaluate ketamine treatment in an animal model of another important psychiatric disease, post-traumatic stress disorder (PTSD). Fifty-eight male rats were initially divided into four groups: Control + Saline (CTRL + SAL), Control + Ketamine (CTRL + KET), PTSD + Saline (PTSD + SAL) and PTSD + Ketamine (PTSD + KET). To mimic PTSD we employed the inescapable footshock protocol. The PTSD animals were classified according to freezing behavior duration into "extreme behavioral response" (EBR) or "minimal behavioral response" (MBR). Afterwards, the glucose metabolism and BDNF were evaluated in the hippocampus, frontal cortex, and amygdala. Our results show that animals classified as EBR exhibited increased freezing behavior and that ketamine treatment further increased freezing duration. Glucose metabolism and BDNF levels showed no significant differences. These results suggest ketamine might aggravate PTSD symptoms and that this effect is unrelated to alterations in glucose metabolism or BDNF protein levels.
Introduction
The Diagnostic and Statistical Manual for Mental Disorders (DSM-5) lists PTSD as a condition related to exposure to a traumatic experience. A traumatic experience is characterized by its ability to induce helplessness, horror and/or fear. Generally, PTSD occurs after a life-threatening event, loss of physical integrity or serious injury [1, 2] . Some of the better known psychophysiological symptoms of PTSD include exaggerated startle, impaired sleep, intrusive memories or flashbacks and the persistent avoidance of trauma associated situations/stimuli [2] . Not all individuals confronted with severe traumatic events develop PTSD. Data on PTSD prevalence in the general population vary from 3 to 8% [3, 4] . However, Kessler et al., [5] reported that 50% of women and 60% of men will have a traumatic experience at some point in their lives. Therefore, this pathology affects a subpopulation of vulnerable individuals exposed to a traumatic experience that exceeds their capacity to cope [1, 2] . Like humans, animals show individual differences in their susceptibility to traumatic stress. Some animals exhibit shorter duration reactions that do not induce prolonged stress responses while others, in spite of being submitted to similar stress situations, exhibit an exacerbated stress response [6] .
Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor for glutamate [7] . It has been used clinically since the 1960s as a dissociative anesthetic agent, although its usage has largely been discontinued due to undesired psychic effects (perceptual alterations such as dissociative experiences), occurring in approximately 12% of patients [8] . However, more recently, ketamine has been shown to produce rapid antidepressant effects as well as decreased suicidal ideation following a single sub-anesthetic dose in depressed patients [9, 10] . In PTSD patients, the results obtained with ketamine are controversial. Some studies have demonstrated positive effects [11] [12] [13] [14] , while others have demonstrated negative effects [7, [15] [16] [17] of ketamine treatment. However, in most cases, ketamine was administered concomitantly with other medications (benzodiazepines, for example). Therefore, it is important to undertake pre-clinical studies to evaluate the independent effects of ketamine.
The most widely accepted hypothesis regarding the mechanisms by which ketamine produces its effects suggests the ketamine-induced NMDA receptor blockade partially impedes activation of eukaryotic elongation factor-2 (eEF2) phosphorylation and consequently reduces the inhibition of BDNF translation. The restoration of BDNF translation promotes the activation of a signaling cascade, resulting in increased synaptic protein and spine density. Therefore, BDNF is thought to have a central role in the action mechanism of ketamine [18] . Moreover, recent neuroimaging studies suggest the fear neurocircuitry may be altered in PTSD. Two of the main symptoms of PTSD: conditioned fear and fear generalization (the transfer of fear experienced during a traumatic event to safe conditions 'resembling' the traumatic event), are associated with changes in the activity of the hippocampus, amygdala and frontal cortex [19] [20] [21] .
In this study, we employed the inescapable footshock protocol as an experimental model of PTSD and the population of stress-exposed rodents was classified according to their individual behavioral response (duration of freezing behavior) [6] . We classified the PTSD animals into two distinct groups: "extreme behavioral response" (EBR) and "minimal behavioral response" (MBR). The goals of this study were to evaluate the brain activity through the 18 F-2-fluoro-2-deoxy-glucose ( 18 F-FDG) uptake and quantify brain derived neurotrophic factor (BDNF) protein in the hippocampus, amygdala and frontal cortex.
Experimental procedures

Animals
All procedures were approved by the University's ethical committee (CEUA 13/00350-PUCRS) and were conducted in accordance with the University's guidelines. Fifty-eight, 12-week-old, male Wistar rats were obtained from the Centro de Modelos Biológicos Experimentais (CeMBE) of the Pontifícia Universidade Católica do Rio Grande do Sul. The rats were kept in standard laboratory conditions with freely available food and water, and a 12:12 h dark/light cycle. In the first part of this study, animals were divided into four groups: 1-Control + Saline (CTRL + SAL, n = 14); 2-Control + Ketamine (CTRL + KET, n = 14); 3-PTSD + Saline (PTSD + SAL, n = 15); 4-PTSD + Ketamine (PTSD + KET, n = 15). Then, after the situational reminder test, the animals from groups 3 and 4 were divided into EBR or MBR according to the behavioral criterion. In the PTSD + SAL group, eight animals were classified as EBR and seven animals as MBR, while in the PTSD + KET group, ten animals were classified as EBR and five animals as MBR.
The PTSD experimental model
In this experimental model, the animals were subjected to a single inescapable footshock [1] . The apparatus consists of a 50 × 25 × 25 cm box separated into two compartments by a removable door. To induce PTSD, the animals were individually positioned in the first compartment, which has a wooden floor. After two minutes, the door was opened and we waited until the animal crossed into the second compartment, in which the floor is a bronze grid. At that moment, the door was closed and then a 1 mA 60 Hz footshock was delivered for 20 s. The animals in the control groups were subjected to the same procedure, but no shock was applied.
Drug administration
A single intraperitoneal injection was applied on the night of the 6th day of the experiment ( Fig. 1) . The ketamine group animals received 10 mg/kg of ketamine (Cristália, Brazil), while the saline group animals received 0.5 ml of saline solution. We chose this ketamine dose, because it has been demonstrated to produce acute and long-lasting antidepressant effects in protocols that mimic depression in animals [22] [23] [24] 45] . The ketamine was administered on 6th day to evaluate the short-term effects of the drug and at the same time to ensure the animals were not subject to a ketamine-induced anesthetic effect.
Situational reminder (SR)
One week after the initial footshock protocol (7th day of the experiment − Fig. 1 ), the animals were exposed to the SR. The animals were positioned in the first compartment of the apparatus for two minutes, but the door dividing the compartments remained closed. In this behavioral test, two experienced researchers evaluated the length of the freezing bout (the average of both time periods provided the value for each animal), which is a measure of conditioned fear.
Cut-off behavioral criterion
Individual animals from the PTSD + SAL and PTSD + KET groups were classified as having either "extreme" or "minimal" behavioral responses according to a pre-established criterion. Here, the average length of the freezing bout of all the animals in the PTSD + SAL group (mean = 14.23 s) was used as the cut-off criterion: animals that froze for over 14.23 s were classified as EBR, while animals that froze for less than 14.23 s were classified as MBR.
18 F-FDG MicroPET scan
Following the behavioral analysis, some animas were randomly selected for 18 F FDG analysis. Only animals from the CTRL + SAL n = 5; CTRL + KET n = 5; PTSD + SAL(EBR) n = 4; and PTSD + KET(EBR) n = 5 groups were submitted to the microPET scanning procedure. On day 8 ( Fig. 1) , the animals received an intravenous injection of 1 mCi of 18 F FDG, and were scanned 40 min after conscious tracer uptake. List mode static acquisitions were acquired for 30 min using a TriumphTM microPET system (LabPET-4, TriFoil Imaging, Northridge, CA, USA). During the scan, the animals were kept under inhalatory anesthesia (induction at 3-4% isoflurane and medical oxygen, and 2-3% for maintenance dose), with body temperature maintained at 36°C. The field of view (FOV; 3.75 cm) was centered on the rat's head. Data were reconstructed using the 3D-MLEM algorithm (3D maximum likelihood estimation method) with 20 iterations. The images were not corrected for attenuation. The Fusion Toolbox (PMOD v3.5, PMOD Technologies, Zurich, Switzerland) was used to spatially normalize the microPET images into an 18 F FDG template. An MRI rat brain VOI template, previously co-registered to the microPET image database, was used to overlay the normalized images [24] . The 18 F FDG uptake in the frontal cortex, hippocampus and amygdala were expressed as standard uptake values (SUVs).
Sample extraction and BDNF determination
To analyze BDNF in the cerebral cortex, the number of animals used from each group was: CTRL + SAL n = 13; CTRL + KET n = 13; PTSD + SAL(EBR) n = 8; PTSD + SAL(MBR) n = 7; PTSD + KET(EBR) n = 10; and PTSD + KET(MBR) n = 4; and in hippocampus the number of animals in each group was: CTRL + SAL n = 14; CTRL + KET n = 14; PTSD + SAL(EBR) n = 8; PTSD + SAL(MBR) n = 7; PTSD + KET(EBR) n = 9; and PTSD + KET(MBR) n = 4. On day 9 of the experiment (Fig. 1) , the animals were decapitated without anesthesia. The rat brains were immediately removed and washed in saline solution. The frontal cortex and hippocampus were dissected out, placed in liquid nitrogen and stored at −80°C until used. For technical reasons, the amygdala was not dissected. The BDNF concentration was determined by ELISA according to the manufacturer's instructions (Millipore, Sandwich ELISA Kit, ChemiKine™).
Data analysis
The data were analyzed using: 1-Pearson's test to evaluate the correlation between the freezing bouts counted by both observers during the SR; 2-Two-way ANOVA, followed by Tukey post hoc tests − to evaluate interactions between "disease status" and "treatment" and differences between groups. The analyses were performed using SPSS 17.0 software. Results are presented as mean ± SE. (p ≤ 0.05).
Results
Freezing behavior
Freezing behavior during the SR is shown in Fig. 2 . The analysis of Pearson's correlation coefficient revealed a strong correlation between the observers (r = 0.981; p < 0.001). The two way ANOVA revealed a significant "disease status" effect (F (2,58) = 52.57; p < 0.001) and a "disease status" X "drug treatment" interaction (F (2,58) = 6.45; p = 0.003) and there was no ketamine effect per se (F (2,58) = 1.94; p = 0.17). Tukey post hoc tests revealed the EBR animals (from both the PTSD + SAL and PTSD + KET groups) presented longer freezing bouts when compared with all the other groups (p < 0.01). Additionally, animals from the PTSD + KET(EBR) group exhibited longer freezing bouts when compared with animals from the PTSD + SAL(EBR) group (p < 0.01). Thus, we observe that our PTSD protocol induced freezing behavior and ketamine interacted positively with this effect, promoting a prolonged freezing bout.
3.2.
F-FDG-MicroPET
The glucose metabolism induced by PTSD, as well as the effect of ketamine treatment are shown in Fig. 3 . The 18 F FDG SUVs showed no significant statistical differences for "disease status" in the frontal cortex (p = 0.951; F (1,15) = 0.004) (Fig. 3a and b) , hippocampus (p = 0.858; F (1,15) = 0.033) (Fig. 3d and e) or amygdala (p = 0.752; F (1,15) = 0.103) (Fig. 3 g and h) . Additionally, no effects were found for "drug treatment" in the frontal cortex (p = 0.637; F (1,15) = 0.231), hippocampus (p = 0.463; F (1,15) = 0.565) or amygdala (p = 0.426; F (1,15) = 0.667). No interaction between "disease status" and "drug treatment" was found.
BDNF protein levels
The effects of PTSD and ketamine treatment on BDNF protein levels are shown in Fig. 3 . No significant differences were observed for "disease status" in the frontal cortex (p = 0.051; F(2,49) = 20.963) (Fig. 3c) or hippocampus (p = 0.365; F(2,50) = 1.028) (Fig. 3f) . Moreover, no additional differences were found for "drug treatment" in the frontal cortex (p = 0.538; F(1,49) = 0.384) or hippocampus (p = 0.822; F(1,50) = 1.339). No interaction between "disease status" and "drug treatment" was found.
Discussion
In this study, we observed that an inescapable footshock protocol as an experimental model of PTSD and treatment with ketamine did not alter the resting glucose metabolism or BDNF protein in the frontal cortex, hippocampus or amygdala of Wistar rats. Moreover, we noted that ketamine treatment increased freezing behavior in the EBR animals.
Our results demonstrate that, as observed in humans, animals show consistent individual differences in their behavioral and physiological response patterns to environmental demands. Regarding freezing behavior, we observed that the PTSD animals classified as MBR presented similar responses to the CTRL + SAL group (Fig. 2) . As reported in other studies, not all stressed animals responded similarly. Some remained unaffected, showing little fear sensitization [25, 26] . Even in highly inbred laboratory strains, genetically identical subjects may be considerably more or less susceptible to similar experimental manipulations [27] . The reasons for these individual differences remain largely unknown, although individual neurobiology and past experience are considered a major risk factor for the development of the disease.
Unlike the MBR animals, the EBR animals (both PTSD + SAL and PTSD + KET) showed longer freezing behavior during the SR when compared to all other groups (Fig. 2) . Freezing behavior is used as a measure of conditioned fear and indicates a sense of intense horror or immediate threat. This behavior suggests the animals developed longlasting anxiety, which is one of the main features of PTSD, because the footshock was remembered 7 days after the exposure. Moreover, the animals from the PTSD + KET group exhibited longer freezing bouts when compared to the PTSD + SAL group. These data demonstrate that, at least in animals exposed to stress, ketamine worsens anxietyrelated behavior. The same result has been described in an experimental PTSD study involving predator-scent stress, which showed that exposed rats treated with 3 different doses of ketamine (0.5, 5 and 15 mg/kg administered one hour following stress exposure) exhibited a significant increase in freezing behavior [7] . A human study demonstrated that 15 trauma-exposed burn subjects who received ketamine/ midazolam as an analgesic/sedative treatment presented significantly more severe PTSD symptoms than subjects who were not given the treatment [15] . Similar results have been described in previous studies involving victims of moderate accidents. Patients who received ketamine during their initial emergency treatment showed an increase in reexperiencing symptoms, elevated dissociative symptoms and heightened avoidance when compared to patients who received opioid medication during their initial treatment [16, 17] . Ketamine is an anesthetic administered especially in military hospitals to burns patients. This drug is associated with psychosis and dissociation, leading to the concern that it may increase the rates of PTSD development [28] . Moreover, some authors suggest that antagonizing the NMDA receptor increases the vulnerability of stressed patients to develop PTSD, because clinical studies propose that NMDA antagonists may transiently stimulate cortico-limbic glutamate release and produce symptoms resembling dissociative states [15, 29] . However, there is no consensus regarding these data, because studies conducted in humans and animals have demonstrated beneficial effects of ketamine in the treatment of PTSD symptoms [11] [12] [13] [14] .
Because the frontal cortex, hippocampus and amygdala are the three major regions involved in the stress response, we decided to analyze the glucose metabolism and BDNF levels in these regions. In our study, we found no change in BDNF expression in any of the analyzed regions nine days after the stress exposure. Our results are in accordance with those reported by previous experimental studies that analyzed the effects of PTSD on long-and short-term BDNF mRNA expression, which showed alterations in BDNF levels are transient and restricted to an hour or a few days [30] [31] [32] [33] . Similarly, a study involving PTSD patients found higher BDNF serum levels in the PTSD group. However, that study also showed that patients who were subjected to trauma exposure in the previous year maintained that difference, while those patients with more remote trauma (more than 1 year) did not [34] . The only study exploring BDNF levels in the cerebrospinal fluid of PTSD patients found no difference when compared with controls [35] . In our study, we evaluated the BDNF levels 9 days after the initial stress. Taken together, the above findings suggest that stress events may dysregulate BDNF signaling, perhaps transiently, thus interfering with the normal functioning of the brain and contributing to the potential development of PTSD. The brain glucose metabolism was analyzed using the 18 F FDGmicroPET technique, which measures the glucose uptake in tissues. In our study, no apparent alterations were observed in the frontal cortex, hippocampus or amygdala. Extant data demonstrating 18 F FDGmicroPET or even cerebral blood flow (CBF) abnormalities in PTSD patients/animal models are limited and conflicting. For example: increased [36] [37] [38] [39] , decreased [36, 40, 41] and unchanged [42, 43] glucose metabolism and CBF have been reported in different nuclei within the amygdala. Similar conflicting results have also been found in different areas of the PFC, with increased [39, 44] and decreased [39, [41] [42] [43] [44] glucose metabolism and CBF being reported. The only consensus seems to be with respect to the hippocampus, in which only decreases in glucose metabolism have been reported [36, 41, 42] . These contradictory results can be attributed to many factors, such as differences in time since the onset of PTSD, heterogeneity of trauma exposure and differences in the paradigms in which the analyses were performed (resting, sleep, trauma-related, trauma-unrelated and neutral scripts). Therefore, it seems that due to PTSD's complex clinical presentation and quite variable symptomatology, it is difficult to establish consistent data about 18 F FDG in this neuropsychiatric condition. Thus, more standardized protocols and nosological classifications of the disease may help clarify these discrepancies.
Other important points should be considered in relation to the effects of ketamine. The classic pathway related to the antidepressant properties of ketamine involves NMDA receptor blockage. However, recent studies have shown that ant depressive effects are in fact generated by ketamine metabolites, (2R,6R)-hydroxynorketamine (HNK), which are responsible for a sustained activation of α-amino-3-hydroxy-5-methyl1-4isoxazole propionic acid (AMPA) receptors [45, 46] . Currently, it is unknown whether the increase duration of freezing bouts found in animals from the PTSD + KET group was associated to NMDA receptor blockage by ketamine or AMPA receptor activation by HNK, or perhaps related to other effects of ketamine and its metabolites in other receptors, such as the: opioid, muscarinic, nicotinic, dopaminergic and serotoninergic receptors [46] . Further studies, testing the effects of ketamine and its metabolites in PTSD models and analyzing different neurotransmission systems, could clarify this point.
Another suggestion for further research is to test PTSD and treatment with ketamine and its metabolites in female rats, since such females have been shown to present an enhanced ant depressive response when compared to males submitted to the same treatment [45] . The same study shows that, after ketamine treatment, the level of HNK is three times higher in the female brain compared to male [45] .
Another interesting topic for future studies about the effects of ketamine in PTSD would be related to the density of stubby and mushroom spines, since a study with postmortem PTSD shows that PTSD promotes an increase in stubby spine density and a trend towards a reduction in mushroom spine density in medial orbital cortex [47] . The same change in spine density was found in the hippocampus of rats using another NMDA receptor antagonist, MK-801 [48] . Indicating that PTSD and NMDA blockage could corroborate to similar changes in dendritic spines.
In summary, the main findings of our study are that acute ketamine treatment increases freezing behavior in PTSD animals. However, this alteration seems to be unrelated to changes in glucose metabolism or BDNF levels in the hippocampus, frontal cortex or amygdala. Moreover, further studies are necessary to better understand the effects of ketamine in PTSD and other psychiatric diseases.
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